To bind or not to bind - FoxA1 determines estrogen receptor action in breast cancer progression

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Watters, Rebecca J ^a   Benos, Panayiotis V ^a   Oesterreich, Steffi ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; DNA BINDING PROTEIN; FOXA1 PROTEIN, HUMAN;

BINDING AFFINITY; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; DYNAMICS; ESTROGEN BINDING; HUMAN; NOTE; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ARTICLE; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM;

BREAST NEOPLASMS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; PROTEIN BINDING; RECEPTORS, ESTROGEN;

EID: 84862494626     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3146     Document Type: Note

References (10)

1. Whyte J, Bergin O, Bianchi A, McNally S, Martin F. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 2009, 11:209. 10.1186/bcr2361, 2790844, 19818165.
2. Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, Wang Q, Liu T, Zhang Y, Brown M, Liu XS. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res 2011, 71:6940-6947. 10.1158/0008-5472.CAN-11-2091, 21940749.
3. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38:1289-1297. 10.1038/ng1901, 17013392.
4. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011, 43:27-33. 10.1038/ng.730, 3024537, 21151129.
5. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43. 10.1016/j.cell.2005.05.008, 16009131.
6. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970. 10.1016/j.cell.2008.01.018, 2323438, 18358809.
7. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010, 24:2219-2227. 10.1101/gad.1944810, 2947773, 20889718.
8. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
9. Fanelli M, Amatori S, Barozzi I, Minucci S. Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. Nat Protoc 2011, 6:1905-1919. 10.1038/nprot.2011.406, 22082985.
10. Fanelli M, Amatori S, Barozzi I, Soncini M, Dal Zuffo R, Bucci G, Capra M, Quarto M, Dellino GI, Mercurio C, Alcalay M, Viale G, Pelicci PG, Minucci S. Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. Proc Natl Acad Sci USA 2010, 107:21535-21540. 10.1073/pnas.1007647107, 3003125, 21106756.